Our Science
With our CAR-T Engager platform, we are building treatments to enhance cell therapies. Our lead candidate, ALETA-001, is focused on eliminating CD19 CAR-T relapses.
Latest News
CAR T Engager proteins optimize anti CD19 CAR T cell therapies for lymphoma
Aleta’s -001 preclinical development paper has been published. This takes Aleta from MOA and efficacy through dose estimation, PK and early protein CMC. Click the link above to read all about it.
Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today released new preclinical results at the 25th American Society of Gene & Cell Therapy Annual Meeting, held in Washington DC and in a virtual platform on May 16-19, 2022. ASGCT is the premier showcase for advances in cell and gene engineering, development and clinical translation.
The presentation featured preclinical data that advance Aleta’s programs in development for the treatment of multiple myeloma and acute myeloid leukemia. These programs leverage the company’s proprietary CAR T Engager technology – multi-antigen targeting systems designed to expand the functionality of conventional cell therapeutics.
Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today released a summary of ALETA-001 preclinical results from a poster being presented at the 63rd American Society of Hematology (ASH) Annual Meeting, held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021.
The presentation featured preclinical data that support the upcoming Phase 1/2 clinical trial of ALETA-001 being run in collaboration with Cancer Research UK. ALETA-001 is a multifunctional biologic for injection that contains an anti-CD20 llama VHH linked to an optimized CD19 protein and further linked to an anti-albumin llama VHH.